AUG 14·SEC EDGARLow
Russell Alan J sold $258K of EWTX
Russell Alan J (Chief Scientific Officer) sold 5,901 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.73 ($43.68–$44.46, $0.26M total) across 3 trades on 2026-08-12.
StockNASDAQ · US · USDHealthcare · Biotechnology
$EWTX
Edgewise Therapeutics, Inc.
Price · $EWTXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $EWTX in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.9M 19 txs
Donovan Joanne M.5× · $413K
10b5-1 share of filings5%
Top stories · $EWTXMore →
AUG 14·SEC EDGAR
MOORE JOHN R sold $220K of EWTX
MOORE JOHN R (General Counsel) sold 5,016 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.82 ($43.80–$44.50, $0.22M total) across 4 trades on 2026-08-12.
AUG 14·SEC EDGAR
Derakhshan Behrad sold $223K of EWTX
Derakhshan Behrad (Chief Business Officer) sold 5,100 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.81 ($43.70–$44.50, $0.22M total) across 4 trades on 2026-08-12.
EWTX sentiment & insider activity
Recent EWTX coverage spans insider activity, mergers & acquisitions and earnings.
In the last 30 days, EWTX insiders filed 19 SEC Form 4 transactions — no purchases and 19 sales ($1.9M). The most active reporter was Donovan Joanne M., CMO, with 5 filings. 5% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving EWTX
The Form 4 shows insider selling, but it is not accompanied by new fundamentals, guidance, or regulatory/clinical catalysts.
The filing discloses an officer open-market sale under a non-10b5-1 plan, which can modestly affect near-term sentiment but not fundamentals.
The filing discloses a fresh insider sale by the company’s Chief Business Officer, which can modestly affect near-term sentiment but does not change fundamentals by itself.
Insider selling by the CEO is a near-term sentiment headwind, but it is not necessarily a fundamental deterioration signal given the lack of 10b5-1 context.
Near-term sentiment should skew positive on the EDG-7500 Phase 2 readout and the balance-sheet strengthening from the sevasemten divestiture, with follow-through dependent on Phase 3 initiation timing.
alphai scores every news story that mentions EWTX with an AI model for sentiment and relevance, and aggregates insider trades from Edgewise Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $EWTX
Score
Russell Alan J sold $258K of EWTX
Russell Alan J (Chief Scientific Officer) sold 5,901 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.73 ($43.68–$44.46, $0.26M total) across 3 trades on 2026-08-12.
1 min readMOORE JOHN R sold $220K of EWTX
MOORE JOHN R (General Counsel) sold 5,016 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.82 ($43.80–$44.50, $0.22M total) across 4 trades on 2026-08-12.
2 min readDerakhshan Behrad sold $223K of EWTX
Derakhshan Behrad (Chief Business Officer) sold 5,100 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.81 ($43.70–$44.50, $0.22M total) across 4 trades on 2026-08-12.
2 min readKOCH KEVIN sold $785K of EWTX
KOCH KEVIN (President and CEO) sold 17,971 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.68 ($43.64–$44.33, $0.79M total) across 3 trades on 2026-08-12.
2 min read
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics (Nasdaq: EWTX) reported Q2 2026 results and said its EDG-7500 12-week Phase 2 CIRRUS-HCM trial showed positive top-line data in obstructive and nonobstructive HCM, with Phase 3 planned for Q4 2026. In July 2026, it completed selling sevasemten and its muscular dystrophy business to Servier for $1.55B upfront plus up to $1.1B milestones. Q2 cash was about $460.7M; net loss was $57.3M.
6 min readEdgewise Therapeutics, Inc. (EWTX): Results of Operations and Financial Condition
Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2026 Financial Results – Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemte
4 min readEdgewise closes muscular-dystrophy biz sale in deal that could top $2.6M
Edgewise Therapeutics Inc. (Nasdaq: EWTX) said it has closed the sale of its muscular-dystrophy business to France’s Les Laboratoires Servier. The transaction includes a drug pipeline led by sevasemten and could be worth up to $2.65 billion, according to the company.
1 min read
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Servier completed its acquisition of Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in regulatory and commercial milestones, after regulatory clearance. The deal adds sevasemten, in a pivotal Becker muscular dystrophy cohort and Phase 2 Duchenne study. (EWTX)
3 min readEdgewise Therapeutics, Inc. (EWTX): Completion of Acquisition or Disposition of Assets
Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001710072 0001710072 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readThursday’s insider activity: Notable buys and strategic sales By Investing.com
Investing.com reports US insider trades disclosed Thursday. Buys: JCTC ($25,871; 11,009 shares at $2.35), BGDE ($16.7M Series D at $1,000), HDSN (~764,202 shares for ~$4.48M), BOLD (~$268,880), and COLB ($22,477). Sells: CRWV CEO sold ~$37.7M; EWTX CSO sold ~$7.88M; ALAB director sold ~$5.62M.
6 min read